CPRX Key Statistics, Chart & Performance
The current stock price of CPRX is 24.13 USD. In the past month the price increased by 1.64%. In the past year, price increased by 7.01%.
CPRX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to CPRX. When comparing the yearly performance of all stocks, CPRX is one of the better performing stocks in the market, outperforming 72.19% of all stocks.
CPRX Fundamental Analysis
ChartMill assigns a fundamental rating of 8 / 10 to CPRX. CPRX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
CPRX Financial Highlights
Over the last trailing twelve months CPRX reported a non-GAAP Earnings per Share(EPS) of 1.72. The EPS increased by 45.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 37.64% | ||
| ROA | 20.69% | ||
| ROE | 23.65% | ||
| Debt/Equity | 0 |
CPRX Forecast & Estimates
14 analysts have analysed CPRX and the average price target is 35.12 USD. This implies a price increase of 45.53% is expected in the next year compared to the current price of 24.13.
For the next year, analysts expect an EPS growth of 24.97% and a revenue growth 19.37% for CPRX
CPRX Ownership
CPRX Latest News, Press Relases and Analysis
About CPRX
Company Profile
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company is headquartered in Coral Gables, Florida and currently employs 181 full-time employees. The company went IPO on 2006-11-08. The firm markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Company Info
CATALYST PHARMACEUTICALS INC
355 Alhambra Circle, Suite 801
Coral Gables FLORIDA 33134 US
CEO: Patrick J. McEnany
Employees: 181
Phone: 13055292522
CATALYST PHARMACEUTICALS INC / CPRX FAQ
What does CATALYST PHARMACEUTICALS INC do?
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company is headquartered in Coral Gables, Florida and currently employs 181 full-time employees. The company went IPO on 2006-11-08. The firm markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
What is the current price of CPRX stock?
The current stock price of CPRX is 24.13 USD. The price increased by 3.21% in the last trading session.
What is the dividend status of CATALYST PHARMACEUTICALS INC?
CPRX does not pay a dividend.
How is the ChartMill rating for CATALYST PHARMACEUTICALS INC?
CPRX has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 8 out of 10.
What is the analyst forecast for CPRX stock?
14 analysts have analysed CPRX and the average price target is 35.12 USD. This implies a price increase of 45.53% is expected in the next year compared to the current price of 24.13.
What is the ex-dividend date for CPRX stock?
The next ex-dividend date for CATALYST PHARMACEUTICALS INC (CPRX) is November 7, 2022.
Would investing in CATALYST PHARMACEUTICALS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CPRX.